复发性肝细胞癌治疗生存决定因素的Meta分析
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients.…
要点
- 短无病间期、多发肝转移和较大肝转移为负性预后因素。
核心结论
- 基于有限数据,复发性HCC患者接受再次肝切除或消融的生存无显著差异。
- 短无病间期、多发肝转移和大肝转移是重要的负性预后因素,可能影响治疗选择。
研究设计与样本
- 系统综述与Meta分析,检索至2016年9月,遵循MOOSE指南。
- 主要结局为不同治疗模式总生存的风险比,采用随机效应模型进行Meta分析。
临床怎么用
- 对于复发性HCC,再次肝切除与消融均可作为可选方案,需结合负性预后因素个体化决策。
- 短无病间期、多发或大肝转移患者可能需更谨慎选择治疗方式。
局限性
- 基于有限数据,证据强度受限。
- 纳入研究均为队列研究,可能存在选择偏倚和异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients. Systematic review and meta-analysis of survival following different treatment modalities may allow improved treatment selection. This review aimed to identify the optimum treatment strategies for HCC recurrence. METHODS: A systematic review, up to September 2016, was conducted in accordance with MOOSE guidelines. The primary outcome was the hazard ratio for overall survival of different treatment modalities. Meta-analysis of different treatment modalities was carried out using a random-effects model, with further assessment of additional prognostic factors for survival. RESULTS: Nineteen cohort studies (2764 patients) were included in final data analysis. The median 5-year survival rates after repeat hepatectomy (525 patients), ablation (658) and transarterial chemoembolization (TACE) (855) were 35·2, 48·3 and 15·5 per cent respectively. Pooled analysis of ten studies demonstrated no significant difference between overall survival after ablation versus repeat hepatectomy (hazard ratio 1·03, 95 per cent c.i. 0·68 to 1·55; P = 0·897). Pooled analysis of seven studies comparing TACE with repeat hepatectomy showed no statistically significant difference in survival (hazard ratio 1·61, 0·99 to 2·63; P = 0·056). CONCLUSION: Based on these limited data, there does not appear to be a significant difference in survival between patients undergoing repeat hepatectomy or ablation for recurrent HCC. The results also identify important negative prognostic factors (short disease-free interval, multiple hepatic metastases and large hepatic metastases), which may influence choice of treatment.
引用
- Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg. 2017. PMID: 28628947. doi:10.1002/bjs.10597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。